Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

BACKGROUND: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti–CTLA-4 treatment prolongs overall survival in patients with melanom...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:N Engl J Med
Päätekijät: Snyder, Alexandra, Makarov, Vladimir, Merghoub, Taha, Yuan, Jianda, Zaretsky, Jesse M., Desrichard, Alexis, Walsh, Logan A., Postow, Michael A., Wong, Phillip, Ho, Teresa S., Hollmann, Travis J., Bruggeman, Cameron, Kannan, Kasthuri, Li, Yanyun, Elipenahli, Ceyhan, Liu, Cailian, Harbison, Christopher T., Wang, Lisu, Ribas, Antoni, Wolchok, Jedd D., Chan, Timothy A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315319/
https://ncbi.nlm.nih.gov/pubmed/25409260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1406498
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia